August 2, 2024 06:00 AM EDT
Financing
Startups

Ex­clu­sive: Ul­tragenyx se­cures first funds for Alzheimer's gene ther­a­py spin­out

Kyle LaHucik

Senior Reporter

Rare dis­ease spe­cial­ist Ul­tragenyx reeled in a $14 mil­lion seed round for its Alzheimer’s gene ther­a­py spin­out Am­logenyx, the com­pa­ny ex­clu­sive­ly told End­points News. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times